{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-287687","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.806079+00:00","generated_at":"2026-06-21T16:54:11.489519+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tenaya Therapeutics prices public offering of ~28.85M shares/warrants for ~$75M gross proceeds","bullets":["Priced public offering of 22,613,307 common shares at $2.60 and 6,236,693 pre-funded warrants at $2.599 per warrant.","Gross proceeds expected ~$75M before expenses; underwriters have 30-day option for up to 4,327,500 additional shares.","Offering expected to close Nov 21, 2022; joint book-runners: Morgan Stanley and Piper Sandler.","Pre-funded warrants have exercise price of $0.001 per share; all securities sold by the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-287687","json":"https://secwatch.observer/filing/0001193125-22-287687.json","markdown":"https://secwatch.observer/filing/0001193125-22-287687.md","text":"https://secwatch.observer/filing/0001193125-22-287687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312522287687/0001193125-22-287687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312522287687/d383621d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:54:11.489519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e909a88428fed3f7dc769356810cc3a59a6721ef","claim":"Tenaya Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives of the several underwriters named therein valued at approximately $75.0 million (effective 2022-11-16).","evidence_excerpt":"On November 16, 2022, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 22,613,307 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $2.60 per share (the “Underwritten Shares”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 6,236,693 shares of the Company’s common stock at a price to the public of $2.599 per underlying share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312522287687/0001193125-22-287687-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives of the several underwriters named therein"},{"label":"Value","value":"approximately $75.0 million"},{"label":"Effective","value":"2022-11-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}